Windlas Biotech stock skyrockets 5% on concluding SAHPRA audit and ahead of Q3 earnings

2 Feb 2022 , 12:20 PM

Windlas Biotech has concluded SAHPRA (South African Health Products Regulatory Authority) inspection audit report for the Plant-IV situated at Dehradun with zero critical observations/ deficiencies, zero major deficiencies and some minor deficiencies.

Hitesh Windlass, Managing Director — Windlas Biotech said, “We are very happy to receive zero critical observations and deficiencies. The successful completion of the audit will enable us to open up new geography and strengthen our presence in South Africa.”

The company had undergone the inspection audit from 20th to 29th September 2021.

Furthermore, the company is set to announce its financial performance for the quarter ending December 2021 (Q3FY22) later today. 

At around 12.17 pm, Windlas Biotech was trading at Rs274.15 per piece up by 4.9% on Sensex. The stock was near the day’s high of Rs279 per piece.